Literature DB >> 18060549

Bladder cancer markers in patient management: the current perspective.

B J Schmitz-Dräger, Y Fradet, H B Grossman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18060549     DOI： 10.1007/s00345-007-0225-0

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  6 in total

Review 1.  Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

Authors:  Peter J Goebell; Susan Groshen; Bernd J Schmitz-Dräger; Richard Sylvester; Manolis Kogevinas; Núria Malats; Guido Sauter; H Barton Grossman; Colin P N Dinney; Fred Waldman; Richard J Cote
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

2.  The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Authors:  Mika-P Raitanen
Journal:  World J Urol       Date:  2008-01-08       Impact factor: 4.226

3.  Delay and survival in bladder cancer.

Authors:  D M A Wallace; R T Bryan; J A Dunn; G Begum; S Bathers
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

4.  Diagnostic delay and prognosis in invasive bladder cancer.

Authors:  Fredrik Liedberg; Harald Anderson; Asa Månsson; Wiking Månsson
Journal:  Scand J Urol Nephrol       Date:  2003

5.  Immunocytology in the assessment of patients with asymptomatic hematuria.

Authors:  B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; J Dörsam; Z Mellan; E Bismarck; T Ebert
Journal:  World J Urol       Date:  2007-12-12       Impact factor: 4.226

Review 6.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226
  6 in total
  2 in total

Review 1.  Statistical consideration for clinical biomarker research in bladder cancer.

Authors:  Shahrokh F Shariat; Yair Lotan; Andrew Vickers; Pierre I Karakiewicz; Bernd J Schmitz-Dräger; Peter J Goebell; Nuria Malats
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

2.  Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.

Authors:  Sahar M Hazzaa; Osama M Elashry; Ibtesam K Afifi
Journal:  Pathol Oncol Res       Date:  2009-09-09       Impact factor: 3.201
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.